Literature DB >> 27879008

Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life.

P V Chernyshov1, L Tomas-Aragones2, L Manolache3, S E Marron4, M S Salek5, F Poot6, A P Oranje7, A Y Finlay8.   

Abstract

There is a need for researchers to have easy reference to the wide spectrum of different types of quality of life (QoL) instruments that can be used in atopic dermatitis (AD). Previous reviews on QoL in AD do not cover the full spectrum of QoL measures used in studies on AD. This study, on behalf of the European Academy of Dermatology and Venereology (EADV) Task Force on QoL, contains information on instruments available for health-related QoL and family QoL assessment in AD including information on validation, experience of QoL assessment in AD for different purposes, peculiarities of QoL assessment in different age groups, expert analysis of available instruments including data on limitations of their use and recommendations of the Task Force.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2017        PMID: 27879008     DOI: 10.1111/jdv.14058

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  9 in total

1.  Assessment of health state utilities in dermatology: an experimental time trade-off value set for the dermatology life quality index.

Authors:  Gábor Ruzsa; Fanni Rencz; Valentin Brodszky
Journal:  Health Qual Life Outcomes       Date:  2022-06-03       Impact factor: 3.077

2.  A Prospective Controlled Study on Long-Term Outcomes of Facial Lacerations in Children.

Authors:  Sonja Fontana; Clemens M Schiestl; Markus A Landolt; Georg Staubli; Sara von Salis; Kathrin Neuhaus; Christoph Mohr; Julia Elrod
Journal:  Front Pediatr       Date:  2021-02-12       Impact factor: 3.418

Review 3.  Quality of Life and Disease Impact of Atopic Dermatitis and Psoriasis on Children and Their Families.

Authors:  Chan Ho Na; Janice Chung; Eric L Simpson
Journal:  Children (Basel)       Date:  2019-12-02

4.  A Real-World Data Study on the Healthcare Resource Use for Uncontrolled Moderate-to-Severe Atopic Dermatitis in Secondary Care in the United Kingdom Prior to the Introduction of Biologic Treatment.

Authors:  Richard D A Hudson; Mahreen Ameen; Susannah M C George; Catherine A Harwood; Richard B Weller; John T Lear; Rajesh Rout; Thishi Surendranathan; Milos Petrovic; Anthony P Bewley
Journal:  Clinicoecon Outcomes Res       Date:  2022-04-04

5.  A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2021-09-22

6.  Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.

Authors:  A Jalili; P Calzavara-Pinton; L Kircik; D Lons-Danic; A Pink; S Tyring; P de la Cueva; M Gooderham; S Segaert; N Nyholm; H Thoning; B Petersen; D Thaçi
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-10-21       Impact factor: 9.228

Review 7.  Quality of Life in Hidradenitis Suppurativa: An Update.

Authors:  Pavel V Chernyshov; Andrew Y Finlay; Lucia Tomas-Aragones; Francoise Poot; Francesca Sampogna; Servando E Marron; Sergey V Zemskov; Damiano Abeni; Thrasyvoulos Tzellos; Jacek C Szepietowski; Christos C Zouboulis
Journal:  Int J Environ Res Public Health       Date:  2021-06-06       Impact factor: 3.390

Review 8.  Counting the Burden: Atopic Dermatitis and Health-related Quality of Life.

Authors:  Faraz Ali; Jui Vyas; Andrew Y Finlay
Journal:  Acta Derm Venereol       Date:  2020-06-09       Impact factor: 3.875

9.  Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic.

Authors:  P V Chernyshov; L Tomas-Aragones; M Augustin; A Svensson; A Bewley; F Poot; J C Szepietowski; S E Marron; L Manolache; N Pustisek; A Suru; C M Salavastru; C Blome; M S Salek; D Abeni; F Sampogna; F Dalgard; D Linder; A W M Evers; A Y Finlay
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-29       Impact factor: 9.228

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.